Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz Group AG (SDZNY) Q1 2026 Sales/Trading Call Transcript
| Specialty Retail Industry | Consumer Discretionary Sector | Richard Saynor CEO | XMUN Exchange | US7999261008 ISIN |
| CH Country | 22,049 Employees | 14 Apr 2026 Last Dividend | - Last Split | - IPO Date |
Sandoz Group AG is a global leader in the development, manufacture, and marketing of generic pharmaceuticals and biosimilars. Established in 1886, the company has its headquarters in Basel, Switzerland. Sandoz operates globally, offering a wide range of therapeutic solutions aimed at improving patient outcomes. Its mission revolves around making high-quality medicines accessible to people worldwide, leveraging its extensive experience and innovation in the pharmaceutical sector.